Viewing data from:

PAROXETINE MESYLATE

ANDA

PAROXETINE MESYLATE | A207139 | ACTAVIS LABORATORIES FL INC

1 strength0 unique patents0 unique exclusivities

Reference Listed Drug: BRISDELLE(TE code: AB)

Medicare Part D Spending

CMS annual spending data for Paroxetine Mesylate (2023)

Total Spending

$644K

Total Claims

2,905

Beneficiaries

1,010

Avg Cost/Unit

$4.23

Spending Trend

$971K(2019)→$916K(2020)→$848K(2021)→$685K(2022)→$644K(2023)

YoY Change:-4.7%

5yr CAGR:-1.2%

Source: CMS Medicare Part D Spending by Drug (2023). Shows gross drug cost under Part D.

API Supply Chain2 active DMFs

2 active API suppliers hold Drug Master Files for this ingredient. Limited supplier base — potential supply chain risk.

ZHEJIANG HUAHAI PHARMACEUTICAL CO LTDPAROXETINE MESYLATE

DMF 280912014

WANBURY LTDPAROXETINE MESYLATE

DMF 305732016

Source: FDA Drug Master Files (fda.gov). Type II API DMFs matched by ingredient.

Approval Letters

1 letter from Drugs@FDA

Date	Submission	Document
Jun 22, 2017	ORIG -1	View Letter (PDF)

Source: Drugs@FDA application documents.

Products (1)

#001 — EQ 7.5MG BASE

0 patents0 exclusivities▴

CAPSULE;ORAL | Approved: Jun 20, 2017

No patent or exclusivity listings for this strength.